Mouse anti Human CD91 antibody, clone A2Mr alpha-2 recognizes human CD91, also known as Prolow-density lipoprotein receptor-related protein 1, Alpha-2-macroglobulin receptor or apolipoprotein E receptor. CD91 is a 4525 amino acid protein post translationally cleaved into 3 subunits, a 85 kDa type I transmembrane carboxyl chain (LRP85) non-covalently bound to a 515 kDa extracellular N-terminal subunit (LRP515)containing multiple EGF-like and LDL-receptor Class A and Class B domains. Additionally, there is an intracellular domain (LRPICD) which can be cleaved from the transmambrane domain by gamma secretase (May et al. 2004). Clone A2Mr alpha-2 detects an epitope within the LRP515 chain.CD91 is a multifunctional protein involved in processes inluding the phagocytosis and endocytosis of apoptotic cells (Nilsson et al. 2012), clearance of activated serum alpha-2-macroglobulin (Kristensen et al. 1990), modulation of the inflammatory response (Staudt et al. 2013) and acts as a receptor for Pseudomonas aeruginosa exotoxin A (Kounnas et al. 1992).Mouse anti Human CD91, clone A2Mr alpha-2 has been used extensively for the detection of CD91 by flow cytometry and immunohistochemistry
Mouse anti Human CD91 antibody, clone A2Mr alpha-2 recognizes human CD91, also known as Prolow-density lipoprotein receptor-related protein 1, Alpha-2-macroglobulin receptor or apolipoprotein E receptor. CD91 is a 4525 amino acid protein post translationally cleaved into 3 subunits, a 85 kDa type I transmembrane carboxyl chain (LRP85) non-covalently bound to a 515 kDa extracellular N-terminal subunit (LRP515)containing multiple EGF-like and LDL-receptor Class A and Class B domains. Additionally, there is an intracellular domain (LRPICD) which can be cleaved from the transmambrane domain by gamma secretase (May et al. 2004). Clone A2Mr alpha-2 detects an epitope within the LRP515 chain.CD91 is a multifunctional protein involved in processes inluding the phagocytosis and endocytosis of apoptotic cells (Nilsson et al. 2012), clearance of activated serum alpha-2-macroglobulin (Kristensen et al. 1990), modulation of the inflammatory response (Staudt et al. 2013) and acts as a receptor for Pseudomonas aeruginosa exotoxin A (Kounnas et al. 1992).Mouse anti Human CD91, clone A2Mr alpha-2 has been used extensively for the detection of CD91 by flow cytometry and immunohistochemistry
Mouse anti Human Apolipoprotein E antibody, clone WUE-4 recognizes an epitope within amino acids 140-160 of human apolipoprotein E (Apo-E), a major component of very low-density lipoproteins (VLDLs). Apo-E is the principle apolipoprotein in the central nervous system, and is secreted by most organs into the plasma, playing a vital role in the binding, internalization and catabolism of triglyceride-rich lipoprotein constituents.Apo-E acts as a ligand for both the specific apo-E receptor (chylomicron remnant) of hepatic tissues, and the apoB,E (LDL) receptor. Three isoforms of Apo-E have been identified, ApoE2, E3 and E4, and have been linked with various disorders. ApoE2 has been shown to bind LPL receptors with low affinity, resulting in increased plasma cholesterol and triglyceride levels, and thereby an increased risk in cardiovascular disorders. ApoE4 is a high risk factor for Alzheimers disease (Sanan et al. 1994), and in particular late onset Alzheimer disease 2 (AD2), whilst ApoE3 is the most common isoform, and considered the normal/natural Apo-E genotype.Mouse anti Human Apolipoprotein E antibody, clone WUE-4 has been shown to inhibit Apo-E mediated binding of lipoproteins to the apoB,E cell receptor (Krul et al. 1998). Storage: This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
Affinity purified using solid phase Human Apolipoprotein E
Purity:
> 95% based on SDS-PAGE
Host:
Goat
Immunogen:
Human Apolipoprotein E
Buffer:
10 mM Sodium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Preservative:
0.05% (w/v) Sodium Azide
Storage:
2-8 °C
Specificity:
Human Apolipoprotein E
Country Of Origin:
Goat serum was obtained from healthy animals of US origin and under the care of a registered veterinarian.
Disclaimer:
For in vitro Laboratory Use Only. Not for diagnostic or therapeutic use. Not for human or animal consumption. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license under any patent of ImmunoReagents, Inc. Product may not be resold or modified for resale without prior written approval of ImmunoReagents, Inc.
Soluble oligomeric assemblies of the Amyloid-β peptide are today anticipated to be the direct cause regarding the Alzheimer pathology. As a consequence, oligomeric Aβ-assemblies constitute a very interesting therapeutic target. Identification of Aβ-oligomers is however, technically challenging due to there labile nature and low abundance. Abeta oligomer-specific OMAB antibody is based on the IgM isotype and represents a new concept of Aβ-oligomer binders using a combination of high avidity and very low monovalent affinity. This combination creates a selectivity of the antibody towards the oligomeric fraction and minimizes reactivity towards monomeric species.
Product Type:
Antibody
Antibody Type:
Monoclonal
Format:
Lyophilized
Storage Temp:
Store lyophilized/reconstituted at 4°C. Please remember to spin the tubes briefly prior to opening them to avoid any losses that might occur from material adhering to the cap or sides of the tube.
Host Animal:
Mouse
Species Reactivity:
Human Abeta oligomers only
Expected Species:
Rat
Immunogen:
partly aggregated, recombinant peptide corresponding to the human Abeta (1-40/42), Amino acid sequence: D-A-E-F-R-H-D-S-G-Y-E-V-H-H-Q-K-L-V-F-F-A-E-D-V-G-S-N-K-G-A-I-I-G-L-M-V-G-G-V-V, The epitope is 3-8, Molecular weight of immunogen is 4,5 kDa,
OMAB antibody is a versatile tool within research of Alzheimer’s disease, A sandwhich ELISA illustrates its potential regarding its high selectivity towards A? oligomers
No confirmed exceptions from predicted reactivity are currently known
Selected references:
Pang et al (2021) An App knock-in rat model for Alzheimer's disease exhibiting A? and tau pathologies, neuronal death and cognitive impairments. Cell Res. 2021 Nov 17. doi: 10.1038/s41422-021-00582-x. Epub ahead of print. PMID: 34789895.Oh et al. (2020). Associative Interactions among Zinc, Apolipoprotein E, and Amyloid-? in the Amyloid Pathology. Int J Mol Sci. 2020 Jan 25;21(3). pii: E802. doi: 10.3390/ijms21030802.Henning-Knechtel et al. (2020). Designed Cell-Penetrating Peptide Inhibitors of Amyloid-beta Aggregation and Cytotoxicity. Cell Reports Physical Science,Volume 1, Issue 2, 26Zhang et al. (2019). Brains of rhesus monkeys display A? deposits and glial pathology while lacking A? dimers and other Alzheimer's pathologies. Aging Cell. 2019 Jun 4:e12978. doi: 10.1111/acel.12978.Kumar et al. (2018). Peptidomimetic-Based Multidomain Targeting Offers Critical Evaluation of A? Structure and Toxic Function. J Am Chem Soc. 2018 May 30;140(21):6562-6574. doi: 10.1021/jacs.7b13401.
Special application note:
OMAB antibody has been purified by by ion-exchange chromatography and is supplied in PBS without any additives as carrier proteins or sodium azide.Binding of OMAB antibody and Abeta oligomers at RT takes about 15 min.Fibrils are inaccessible for OMAB antibodies therefore if a discrimination between fibrils and oligomers is to be achieved, dot blot can be used. Start with antigen concentration of 500 ng/dot followed by 2X dilution steps. Blocking: non-fat milk and washes with 0.3 % Tween 20 in TBS pH 7.4.
The amyloid beta peptide is derived from the cleavage of the Amyloid precursor protein (APP) and varies in length from 39 to 43 amino acids. However, the form(s) of amyloid-beta peptide (A? associated with the pathology characteristic of Alzheimer's disease (AD) remains unclear. In particular, the neurotoxicity of intraneuronal A? accumulation is an area of considerable research and controversy principally because antibodies thought to be specific for A? have been shown to actually detect intraneuronal APP and not A? exclusively.<br /><br />MOAB-2 (mouse IgG2b) is a pan-specific, high-titer antibody to A? residues 1-4 as demonstrated by biochemical and immunohistochemical analyses (IHC), and is highly specific just to amyloid beta peptide. <strong>MOAB-2 did not detect APP or APP-CTFs</strong> in cell culture media/lysates (HEK-APPSwe or HEK APPSwe/BACE1) or in brain homogenates from transgenic mice expressing 5 familial AD (FAD) mutation (5xFAD mice). <br /><br />Using IHC on 5xFAD brain tissue, MOAB-2 immunoreactivity co-localized with C-terminal antibodies specific for A?40 and A?42. MOAB-2 did not co-localize with either N- or C-terminal antibodies to APP. In addition, no MOAB-2-immunreactivity was observed in the brains of 5xFAD/BACE-/- mice, although significant amounts of APP were detected by N- and C-terminal antibodies to APP, as well as by 6E10. In both 5xFAD and 3xTg mouse brain tissue, MOAB-2 co-localized with cathepsin-D, a marker for acidic organelles, further evidence for intraneuronal A?, distinct from A? associated with the cell membrane. MOAB-2 demonstrated strong intraneuronal and extra-cellular immunoreactivity in 5xFAD and 3xTg mouse brain tissues.<br /><br />Biosensis now offers <strong>biotinylated MOAB-2</strong> <strong>antibody</strong> allowing more flexibility in experimental design by using the biotin-avidin/streptavidin detection method. Biotinylated MOAB-2 antibody may also help to reduce background staining in difficult-to-stain tissues and increase detection sensitivity. The ability of biotinylated MOAB-2 antibody to detect amyloid beta has been validated by IHC.<br /><br />Purified, non-biotinylated MOAB-2 antibody is available <a href="https://www.biosensis.com/moab-mouse-monoclonal-antibody-amyloid-beta-peptide-beta-4042-purified-p-1181.htmL">here</a>.
Product Type:
Antibody
Antibody Type:
Monoclonal
Format:
Lyophilized from PBS buffer, pH 7.4; contains no preservative.
Host Animal:
Mouse
Species Reactivity:
Human,Rat
Immunogen:
Recombinant human amyloid beta protein 42 (A?42): DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
Applications:
ELISA,ICC,IHC-Frozen,IHC-Paraffin-embedded,IP,WB
Clone number:
MOAB-2
Antibody Isotype:
IgG2b, lambda
Application Details:
The biotinylated MOAB-2 antibody has been tested by IHC (1:500 - 1:2,000 dilution) and is also expected to work in applications validated for the unlabelled antibody (M-1586-100) at same or higher dilutions: Western Blotting (WB), Immunohistochemistry (IHC), Immunohistochemistry/paraffin embedded IHC(P), Immunoprecipitation (IP), Immunofluorescence (IF), ELISA.<br><br><i>Western Blotting:</i><br><br>MOAB-2 has been tested in WB using purified synthetic beta-amyloid preparations and from transgenic mouse brain formic acid extracts (see Figure 1). Formic acid extraction/concentration is required for western blot detection from extracts. Suggested dilution of 1:2000-1:5,000 for WB, standard ECL detection systems. <br><br>Tissue samples for the detection of beta-amyloid should be prepared as detailed in Youmans KL et al., 2011 (Journal of Neuroscience Methods 196: 51-59) for best results. Detection of beta-amyloid 40/42 in direct westerns can be difficult; Dot-blots of prepared samples are recommended as detailed in Youmans KL et al., 2012. <br><br><i>Immunohistochemistry:</i><br><br>Suggested dilution for biotinylated MOAB-2 in IHC is 1:500-1:2,000. Fresh frozen, 4% paraformaldehyde fixed frozen, or formalin fixed paraffin embedded tissues are all suitable. Antigen retrieval is required in fixed tissues for optimal staining.<br><br>Antibody was tested on 4% paraformaldehyde/0.1% glutaraldehyde fixed frozen tissue from 3xTg and 5xFAD mice. MOAB-2 antibody detects intraneuronal and extracellular beta-amyloid in IHC and does not detect APP (Youmans KL et al., 2012).<br><br>The antibody also reacts with archival formalin-fixed, paraffin-embedded tissue samples with antigen Heat Induced Epitope Retrieval (HIER). Recommended buffer for HIER is citrate, pH 6.0. Signal was weak without antigen retrieval. Immunoreactivity was observed in intraneural-amyloid deposition (plaque) in Alzheimer's brain. MOAB-2 was found to be extremely clean and with an excellent signal to noise ratio with no neuro-cellular diffusive staining.<br><br>In addition, MOAB-2 demonstrated no significant differences in A-beta detection using paraffin fixed, free-floating sections (Youmans KL et al., 2012). Formic acid (FA) treatment resulted in optimal detection of both intraneuronal and extracellular A-beta compared to without FA (incubated in 88% FA 8 min, Youmans KL et al., 2012). Free floating tissue sections were permeabilized in TBS containing 0.25% Triton X-100 (TBSX; 3 x 10 min), blocked with 3% horse serum in TBSX (3 x 10 min) followed by 1% horse serum in TBSX (2 x10 min) and incubated with appropriate primary antibodies diluted in TBSX containing 1% horse serum overnight. See Youmans KL et al., 2012, for full IHC(P) protocol and method details.<br><br><i>Immunofluorescence:</i><br><br>For IF, suggested dilution is 1:100-1:500. The antibody was tested on 4% PFA fixed frozen tissue. Fixed tissues were washed in TBS (3 x 10 min), then incubated in 88% FA (8 min), and then permeabilized in TBSX (3 x 10 min), and blocked in TBSX containing 5% bovine serum albumin (BSA; 1 hr). Sections were subsequently incubated with appropriate primary antibodies diluted in TBSX containing 2% BSA overnight on an oscillatory rotator. Detection was via fluorescently labelled absorbed secondary antibodies (Youmans KL et al., 2012).<br><br><i>Immunoprecipitation:</i><br><br>For IP, the suggested dilution is 1:200 to 1:1,000 for labelled beta-amyloid using SA-coated beads as the capture vehicle, similar to the protocols employed by Youmans KL et al., 2012.<br><br><i>ELISA:</i><br><br>In an ELISA, a dilution of 1:50-1:1,000 is suggested. The antibody has been tested in ELISAs on synthetic beta-amyloid and tissue homogenates from beta-amyloid-Tg mice. <br><br>Biosensis recommends optimal dilutions/concentrations should be determined by the end user for all applications. Dilutions provided are only meant to serve as a basic guide.
Kim, S. et al. (2020) Performance Validation of a Planar Hall Resistance Biosensor through Beta-Amyloid Biomarker. Sensors (Basel). 20(2) Application: In-vitro biosensor. Ruan, CS. et al. (2017) Sortilin inhibits amyloid pathology by regulating non-specific degradation of APP. Exp Neurol. [Epub ahead of print] Application: IHC References for non-biotinylated MOAB-2 antibody (M-1586-100): Zhu, B. et al. (2017) ER-associated degradation regulates Alzheimer's amyloid pathology and memory function by modulating _-secretase activity. Nat Commun. 8(1):1472. Application: IHC Huang, TY. et al. (2017) SORLA attenuates EphA4 signaling and amyloid _-induced neurodegeneration. J Exp Med. pii: jem.20171413. [Epub ahead of print]. Application: IHC Felecia, M. et al. (2017) Peripheral Inflammation, Apolipoprotein E4, and Amyloid-_ Interact to Induce Cognitive and Cerebrovascular Dysfunction. ASN Neuro. 9(4):1759091417719201. Application: IHC/IF Thomas, R. et al. (2016) Epidermal growth factor prevents APOE4 and amyloid-beta-induced cognitive and cerebrovascular deficits in female mice. Acta Neuropathol Commun. 4(1):111 Application: IHC Koster, KP. et al. (2016) Epidermal growth factor prevents oligomeric amyloid-_ induced angiogenesis deficits in vitro. J Cereb Blood Flow Metab. [Epub ahead of print] Application: IF Loffler, T. et al. (2016) Decreased Plasma A? in Hyperlipidemic APPSL Transgenic Mice Is Associated with BBB Dysfunction. Front. Neurosci. Application: IF Kobro-Flatmoen, A. et al. (2016) Reelin-immunoreactive neurons in entorhinal cortex layer II selectively express intracellular amyloid in early Alzheimer's disease. Neurobiology of Disease. 93:172-183. Application: IHC Tai, LM. et al. (2016) The role of APOE in cerebrovascular dysfunction. Acta Neuropathol. 131(5):709-23. Application: IF Kim, YH. et al. (2015) A 3D human neural cell culture system for modeling Alzheimer's disease. Nat Prot. 10(7):985-1006. Application: WB Condello, C. et al. (2015) Microglia constitute a barrier that prevents neurotoxic protofibrillar A?42 hotspots around plaques. Nat Commun. 6:6176. Application: IF Iulita MF et al (2014) Intracellular Abeta pathology and early cognitive impairments in a transgenic rat model overexpressing human amyloid precursor protein: a multidimensional study. Acta Neuropathol Commun. 6:61. Application: IF, IH Smith BR et al (2014) Neuronal inclusions of alpha-synuclein contribute to the pathogenesis of Krabbe disease. J Pathol. Apr;235(5):509-21. Application: IF
Specificity:
MOAB-2 detects preparations enriched in U-, O-, F-A?42, and U-A?40 by dot-blot, and is thus a pan-specific A? antibody. However, MOAB-2 is selective for the more neurotoxic A?42 compared to A?40. Indeed, MOAB-2 demonstrated a titration against antigen concentration, and detects A?40 at 2.5 pmol, but U-, O- and F-A?b42 at antigen concentrations as low as ~ 0.1 pmol (Youmans. KL et al., 2012; PMID: 22423893). MOAB-2 does not detect APP (Amyloid Precursor Protein). Human, rat, other species not yet tested. By Dot Blot, MOAB-2 detected rat A?40 and human A?40, albeit with less affinity than for A?42 (Youmans KL et al., 2012).
Storage:
After reconstitution keep aliquots at -20°C to -70°C for a higher stability. At 2-8°C keep up to one week; use sterile methods and pipettes. Highly purified glycerol (1:1) may be added for an additional stability. Avoid repetitive freeze/thaw cycles. Keep tightly closed when not in use and protected from light.
Purification:
Antibody was purified from cell culture supernatant by Protein G chromatography, biotinylated and buffer-exchanged into PBS, pH 7.4 buffer
The amyloid beta peptide is derived from the cleavage of the Amyloid precursor protein (APP) and varies in length from 39 to 43 amino acids. However, the form(s) of amyloid-beta peptide (A? associated with the pathology characteristic of Alzheimer's disease (AD) remains unclear. In particular, the neurotoxicity of intraneuronal A? accumulation is an area of considerable research and controversy principally because antibodies thought to be specific for A? have been shown to actually detect intraneuronal APP and not A? exclusively.<br /><br />MOAB-2 (mouse IgG2b) is a pan-specific, high-titer antibody to A? residues 1-4 as demonstrated by biochemical and immunohistochemical analyses (IHC), and is highly specific just to amyloid beta peptide.<br /><br />MOAB-2 did not detect APP or APP-CTFs in cell culture media/lysates (HEK-APPSwe or HEK APPSwe/BACE1) or in brain homogenates from transgenic mice expressing 5 familial AD (FAD) mutation (5xFAD mice). <br /><br />Using IHC on 5xFAD brain tissue, MOAB-2 immunoreactivity co-localized with C-terminal antibodies specific for A?40 and A?42. MOAB-2 did not co-localize with either N- or C-terminal antibodies to APP. In addition, no MOAB-2-immunreactivity was observed in the brains of 5xFAD/BACE-/- mice, although significant amounts of APP were detected by N- and C-terminal antibodies to APP, as well as by 6E10.<br /><br />In both 5xFAD and 3xTg mouse brain tissue, MOAB-2 co-localized with cathepsin-D, a marker for acidic organelles, further evidence for intraneuronal A?, distinct from A? associated with the cell membrane. MOAB-2 demonstrated strong intraneuronal and extra-cellular immunoreactivity in 5xFAD and 3xTg mouse brain tissues.
Product Type:
Antibody
Antibody Type:
Monoclonal
Format:
Lyophilized, from a Protein A purified preparation in 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, 0.01% sodium azide, 0.1% trehalose, pH 7.2; contains 0.01% sodium azide as a preservative.
Host Animal:
Mouse
Species Reactivity:
Human,Rat
Immunogen:
Recombinant human amyloid beta protein 42 (A?42): DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
Western Blotting (WB), Immunohistochemistry (IHC), Immunohistochemistry/paraffin embedded IH(P), Immunoprecipitation (IP), Immunofluorescence (IF), ELISA.<br><br>Antibody has been tested in WB using purified synthetic beta-amyloid preparations and from transgenic mouse brain formic acid extracts (see figure 1). Formic acid extraction/concentration is required for western blot detection from extracts. MOAB-2 antibody is specific for beta-amyloid and does not detect APP. Suggested dilution of 1:2000-1:5,000 for WB, standard ECL detection systems. <br><br>Tissue samples for the detection of beta-amyloid should be prepared as detailed in K.L. Youmans et al. {Journal of Neuroscience Methods 196 (2011) 51-59} for best results. Detection of beta-amyloid 40/42 in direct westerns can be difficult; Dot-blots of prepared samples are recommended as detailed in Youmans. KL et al 2012. <br><br>IR or fluorescent detection systems not yet tested, they but are expected to work well with higher primary antibody dilutions because of the increased sensitivity of the detection methods.<br><br>Suggested dilutions for IHC are 1:50-1:1,000. Fresh frozen, 4% paraformaldehyde fixed frozen, or formalin fixed paraffin embedded tissues are all suitable. Optimal dilutions must be determined by the end user. Antigen retrieval is required in fixed tissues for optimal staining.<br><br>Antibody was tested on 4% paraformaldehyde/0.1% glutaraldehyde fixed frozen tissue from 3xTg and 5xFAD mice. MOAB-2 antibody detects intraneuronal and extracellular beta-amyloid in IHC and does not detect APP {Youmans KL et al 2012}.<br><br> The antibody also reacts with archival formalin-fixed, paraffin-embedded tissue samples with antigen Heat Induced Epitope Retrieval (HIER): Recommended Citrate, pH 6.0 buffer for HIER. Signal was weak without antigen retrieval. Immunoreactively was expressed in intraneural-amyloid deposition (plaque) in Alzheimer's brain. MoAB-2 was found to be extremely clean and with an excellent signal to noise ratio with no neuro-cellular diffusive staining.<br><br>In addition MOAB-2 demonstrated no significant differences in A-beta detection using paraffin fixed, free-floating sections {Youmans KL et al 2012}. Formic acid (FA) treatment resulted in optimal detection of both intraneuronal and extracellular A-beta compared to without FA (incubated in 88% FA 8 min, Youmans KL et al 2012). Free floating tissue sections were permeabilized in TBS containing 0.25% Triton X-100 (TBSX; 3 x 10 min), blocked with 3% horse serum in TBSX (3 x 10 min) followed by 1% horse serum in TBSX (2 x10 min) and incubated with appropriate primary antibodies diluted in TBSX containing 1% horse serum overnight. See Youmans KL et al 2012 for full IH(P) protocol and method details.<br><br> For IF, suggested dilution is 1:100-1:500. The antibody was tested on 4% PFA fixed frozen tissue. Fixed tissues were washed in TBS (3 x 10 min), then incubated in 88% FA (8 min), and then permeabilized in TBSX (3 x 10 min), and blocked in TBSX containing 5% bovine serum albumin (BSA; 1 hr). Sections were subsequently incubated with appropriate primary antibodies diluted in TBSX containing 2% BSA overnight on an oscillatory rotator. Detection was via fluorescently labelled absorbed secondary antibodies {Youmans KL et al 2012}.<br><br>For IP, the suggested dilution is 1:200 to 1:1,000 for labeled beta-amyloid using Protein A/G conjugated beads as the capture vehicle {Youmans KL et al 2012}.<br><br>In an ELISA, a dilution of 1:50-1:1000 is suggested. The antibody has been tested in ELISAs on synthetic beta-amyloid and tissue homogenates from beta-amyloid-Tg mice. Biosensis recommends optimal dilutions/concentrations should be determined by the end user for all applications. Dilutions provided are only meant to serve as a basic guide.
Alternative Names:
Beta-APP42; Beta-APP40; Beta-amyloid protein 42; Beta-amyloid protein 40; ABPP; APPI; Amyloid beta A4 protein;MOAB2;MOAB-2; Alzheimer's antibody;AB40;AB42;abeta
Biosensis Brand:
Biosensis®
Conjugate:
Unconjugated
Shelf Life:
12 months after date of receipt (unopened vial).
Use:
For research use only.
Product references:
Setti, S.E. et al. (2022) Assessment of sex-related neuropathology and cognitive deficits in the Tg-SwDI mouse model of Alzheimers disease. Behave Brain Res. 428:113882. Application: IHC. Sil, A. et al. (2022) Sex Differences in Behavior and Molecular Pathology in the 5XFAD Model. J Alzheimers Dis. 85(2):755-778. Application: WB. Sarkar, S. et al. (2020) Modification of methods to use Congo-red stain to simultaneously visualize amyloid plaques and tangles in human and rodent brain tissue sections. Metab Brain Dis. [Epub ahead of print]. Application: IHC. Cuevas, E. et al. (2019) Amyloid Beta 25-35 induces blood-brain barrier disruption in vitro. Metab Brain Dis. [Epub ahead of print]. Application: ICC/IF. Schmued, L. et al. (2019) High Contrast and Resolution Labeling of Amyloid Plaques in Tissue Sections from APP-PS1 Mice and Humans with Alzheimer's Disease with the Zinc Chelator HQ-O: Practical and Theoretical Considerations. Curr Alzheimer Res. 16(7):577-586. Application: IHC/IF. Hui, L. et al. (2019) Acidifying Endolysosomes Prevented Low-Density Lipoprotein-Induced Amyloidogenesis. J Alzheimers Dis. 64(1):393-410. Application: ICC/IF. Koss, DJ. et al. (2018) Distinctive temporal profiles of detergent-soluble and -insoluble tau and A? species in human Alzheimer's disease. Brain Res. [Epub ahead of print]. Application: WB, dot blot. Zhao, Y. et al. (2018) TREM2 Is a Receptor for _-Amyloid that Mediates Microglial Function. Neuron. 97(5):1023-1031. Application: IHC, free-floating cryostat sections Zhu, B. et al. (2017) ER-associated degradation regulates Alzheimer's amyloid pathology and memory function by modulating _-secretase activity. Nat Commun. 8(1):1472. Application: IHC Huang, TY. et al. (2017) SORLA attenuates EphA4 signaling and amyloid _-induced neurodegeneration. J Exp Med. pii: jem.20171413. [Epub ahead of print]. Application: IHC Felecia, M. et al. (2017) Peripheral Inflammation, Apolipoprotein E4, and Amyloid-_ Interact to Induce Cognitive and Cerebrovascular Dysfunction. ASN Neuro. 9(4):1759091417719201. Application: IHC/IF Thomas, R. et al. (2016) Epidermal growth factor prevents APOE4 and amyloid-beta-induced cognitive and cerebrovascular deficits in female mice. Acta Neuropathol Commun. 4(1):111 Application: IHC Koster, KP. et al. (2016) Epidermal growth factor prevents oligomeric amyloid-_ induced angiogenesis deficits in vitro. J Cereb Blood Flow Metab. [Epub ahead of print] Application: IF Loffler, T. et al. (2016) Decreased Plasma A? in Hyperlipidemic APPSL Transgenic Mice Is Associated with BBB Dysfunction. Front. Neurosci. Application: IF Kobro-Flatmoen, A. et al. (2016) Reelin-immunoreactive neurons in entorhinal cortex layer II selectively express intracellular amyloid in early Alzheimer's disease. Neurobiology of Disease. 93:172-183. Application: IHC Tai, LM. et al. (2016) The role of APOE in cerebrovascular dysfunction. Acta Neuropathol. 131(5):709-23. Application: IF Kim, YH. et al. (2015) A 3D human neural cell culture system for modeling Alzheimer's disease. Nat Prot. 10(7):985-1006. Application: WB Condello, C. et al. (2015) Microglia constitute a barrier that prevents neurotoxic protofibrillar A?42 hotspots around plaques. Nat Commun. 6:6176. Application: IF Iulita MF et al (2014) Studying Alzheimer's Disease Pre-clinical Stages: Insights from Down's Syndrome and Transgenic Animal Models. PhD Thesis Application: IHC/IF Iulita MF et al (2014) Intracellular Abeta pathology and early cognitive impairments in a transgenic rat model overexpressing human amyloid precursor protein: a multidimensional study. Acta Neuropathol Commun. 6:61. Application: IF, IH Smith BR et al (2014) Neuronal inclusions of alpha-synuclein contribute to the pathogenesis of Krabbe disease. J Pathol. Apr;235(5):509-21. Application: IF
Specificity:
MOAB-2 detects preparations enriched in U-, O-, F-A?42, and U-A?40 by dot-blot, and is thus a pan-specific A? antibody. However, MOAB-2 is selective for the more neurotoxic A?42 compared to A?40. Indeed, MOAB-2 demonstrated a titration against antigen concentration, and detects A?40 at 2.5 pmol but U-, O- and FA?b42 at antigen concentrations as low as ~ 0.1 pmol {Youmans. KL et al 2012}. MOAB-2 does not detect APP (Amyloid precursor protein). Human, Rat, other species not yet tested.By Dot blot, MOAB-2 detected rat A?40 and human A?40, albeit with less affinity than for A?42. {Youmans. KL et al 2012}
Storage:
After reconstitution keep aliquots at -20 ° to -70°C for a higher stability. At 2-8°C keep up to one week, insulated, protected from light; use sterile methods and pipettes. Highly purified glycerol (1:1) may be added for an additional stability. Avoid repetitive freeze/thaw cycles. Keep tightly closed when not in use and protected from light.
Purification:
This product is a Protein A purified mouse IgG2b in 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, 0.01% sodium azide, pH 7.2.
Goat anti-Apolipoprotein E (ApoE) Polyclonal Antibody (Unconjugated), suitable for ELISA.
Background Info:
Apolipoprotein E (ApoE) is a lipoprotein involved in fat metabolism and acts as cholesterol carrier between cells and across tissues. On a genetic level, three APOE alleles are described, APOE2, APOE3 and APOE4. These alleles give rise to six APOE isoforms, which are differentially implicated in various diseases. In the peripheral system, APOE4 is linked to increased risk of atherosclerosis. In the CNS, the ability of APOE4 in clearing beta-amyloid is impaired, while APOE3 and APOE2 are more efficient in performing this task. The APOE4 genotype in particular has been linked to increased risk for developing Alzheimer's Disease.
Product Type:
Antibody
Antibody Type:
Polyclonal
Format:
Lyophilized from a solution containing 50 mM Tris, pH 7.5, 0.4 M NaCl, 0.01 M EDTA, 3% trehalose, 0.07% sodium azide.
Host Animal:
Goat
Species Reactivity:
Human
Immunogen:
Recombinant human Apolipoprotein E
Applications:
ELISA
Antibody Isotype:
IgG
Application Details:
ELISA (0.1-1 µg/mL). Other applications not tested as yet. Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
Alternative Names:
APOE;
Biosensis Brand:
Biosensis®
Conjugate:
Unconjugated
Shelf Life:
12 months after date of receipt (unopened vial).
Use:
For research use only.
Specificity:
Human. Species cross-reactivity not tested.
Storage:
Store lyophilized antibody at 2-8°C. After reconstitution keep aliquots at -20°C to -80°C for higher stability. Avoid repetitive freeze/thaw cycles.
Biosensis is proud to offer the first commercially available ApoE/?-amyloid (ApoE/A?) complex ELISA kit. As a result of extensive collaboration with Dr. LaDu's laboratory at UIC and validation by Biosensis, this ELISA can be used to accurately and consistently measure the extent of ApoE/A? complex in tissue extracts and other samples. The Biosensis ApoE/A? Complex ELISA kit is a sandwich ELISA and consists of a pre-coated mouse monoclonal anti-A? capture antibody, a highly validated ApoE/A? complex standard that is pre-formed, lyophilized and ready for reconstitution, a biotinylated ApoE detection antibody, and horseradish peroxidase (HRP)-conjugated streptavidin and detection reagent. The addition of a substrate (3,3',5,5'-tetramethylbenzidine, TMB) yields a colored reaction product which is directly proportional to the level of ApoE/A? complex present in samples and protein standards. Importantly, a well-characterized and unique ApoE/A? complex is included as a standard. This complex is pre-formed and lyophilized, requiring only reconstitution with assay diluent prior to use. In order to assess non-specific ApoE protein binding, each kit includes additional plates pre-coated with control antibody. The purpose of this kit is the in vitro qualitative measurement of ApoE/A? complexes in brain extracts and CSF samples from both transgenic mice and humans or primates, relative to a known ApoE/A? complex standard, only if used as directed. This kit has not been tested for other sample applications. This kit has been configured for research use only and is not to be used in diagnostic or clinical procedures.
Product Type:
ELISA Assay
Species Reactivity:
Human
Immunogen:
Complex of E.coli-derived recombinant human ApoE protein and synthetic, monomerized Abeta (1-42) peptide
Applications:
ELISA
Application Details:
ELISA. For the quantification of Apolipoprotein E/beta-Amyloid Complex (ApoE/A beta) in CSF, Tissue Homogenates. Please download the detailed product insert for complete instructions for the successful use of this ELISA. Use only as directed.
The ELISA kit box contains 2 x 96-well pre-coated strip plates per 1 Plate Kit (1 plate MOAB-2 antibody coated, 1 plate control antibody coated), protein standards, detection reagents, wash and sample buffers, substrate buffer and detailed protocols.
Product references:
Tai LM et al. (2013) J Biol Chem. 288(8): 5914-26 Tai LM et al. (2014) Mol Neurodegen. 9:2
Specificity:
Human Apolipoprotein E/beta-Amyloid (ApoE/A beta) Complex. The kit has been assayed on human samples only but the capture antibody, MOAB-2, is know to react with rodent amyloid beta though weaker (20% less reactivity on dot blots). The polyclonal APOE used for detection should detect ApoE from a variety of species but so far has only been tested on human
Biosensis is proud to offer the first commercially available ApoE/?-amyloid (ApoE/A?) complex ELISA kit. As a result of extensive collaboration with Dr. LaDu's laboratory at UIC and validation by Biosensis, this ELISA can be used to accurately and consistently measure the extent of ApoE/A? complex in tissue extracts and other samples. The Biosensis ApoE/A? Complex ELISA kit is a sandwich ELISA and consists of a pre-coated mouse monoclonal anti-A? capture antibody, a highly validated ApoE/A? complex standard that is pre-formed, lyophilized and ready for reconstitution, a biotinylated ApoE detection antibody, and horseradish peroxidase (HRP)-conjugated streptavidin and detection reagent. The addition of a substrate (3,3',5,5'-tetramethylbenzidine, TMB) yields a colored reaction product which is directly proportional to the level of ApoE/A? complex present in samples and protein standards. Importantly, a well-characterized and unique ApoE/A? complex is included as a standard. This complex is pre-formed and lyophilized, requiring only reconstitution with assay diluent prior to use. In order to assess non-specific ApoE protein binding, each kit includes additional plates pre-coated with control antibody. The purpose of this kit is the in vitro qualitative measurement of ApoE/A? complexes in brain extracts and CSF samples from both transgenic mice and humans or primates, relative to a known ApoE/A? complex standard, only if used as directed. This kit has not been tested for other sample applications. This kit has been configured for research use only and is not to be used in diagnostic or clinical procedures.
Product Type:
ELISA Assay
Species Reactivity:
Human
Immunogen:
Complex of E.coli-derived recombinant human ApoE protein and synthetic, monomerized Abeta (1-42) peptide
Applications:
ELISA
Application Details:
ELISA. For the quantification of Apolipoprotein E/beta-Amyloid Complex (ApoE/A beta) in CSF, Tissue Homogenates. Please download the detailed product insert for complete instructions for the successful use of this ELISA. Use only as directed.
The ELISA kit box contains 2 x 96-well pre-coated strip plates per 1 Plate Kit (1 plate MOAB-2 antibody coated, 1 plate control antibody coated), protein standards, detection reagents, wash and sample buffers, substrate buffer and detailed protocols.
Product references:
Tai LM et al. (2013) J Biol Chem. 288(8): 5914-26 Tai LM et al. (2014) Mol Neurodegen. 9:2
Specificity:
Human Apolipoprotein E/beta-Amyloid (ApoE/A beta) Complex. The kit has been assayed on human samples only but the capture antibody, MOAB-2, is know to react with rodent amyloid beta though weaker (20% less reactivity on dot blots). The polyclonal APOE used for detection should detect ApoE from a variety of species but so far has only been tested on human
The oligomeric form of Amyloid Beta peptide (A?, 1-42) has been closely linked to Alzheimer's Disease. Several ELISAs targeting A? have been developed; however, these ELISAs are known to cross-react with Amyloid Beta precursor protein (APP) and are poorly characterized against monomeric and oligomeric forms of the peptide. The Biosensis MOAB-2 antibody, developed by LaDu and co-workers (Youmans K. et al. , 2012) , has been shown to specifically detect A?, but not the precursor molecule APP. When utilized in ELISAs, the oligomeric form of A? peptide (o-A?) can be assayed independently of the other forms of the molecule when assayed with the MOAB-2 monoclonal antibody. The Biosensis oligomeric A? ELISA kit is a sandwich ELISA that allows the preferential quantification of oligomeric A? peptides. This kit is exclusive to Biosensis and consists of a pre-coated mouse monoclonal anti-A? capture antibody (MOAB-2), a biotinylated MOAB-2 detection antibody and horseradish peroxidase (HRP)-conjugated streptavidin. The addition of a substrate (3,3',5,5'-tetramethylbenzidine, TMB) yields a colored reaction product which is directly proportional to the concentration of o-A? present in samples and protein standards. The purpose of this kit is the in vitro qualitative measurement of oligomeric A? peptide levels in brain extracts and CSF samples from both transgenic mice and humans relative to a known o-A? standard. The inclusion of a highly validated oligomeric standard results in a unique, ready-to-use ELISA kit. This kit has been configured for research use only and is not to be used in diagnostic or clinical procedures.
Product Type:
ELISA Assay
Species Reactivity:
Human,Rat
Immunogen:
The standard in this ELISA is synthetically manufactured beta-amyloid peptide, amino acids 1-42 of human, HFIP treated and dried.The stabilized oligomeric beta amyloid 1-42 control complex is also constructed from the same synthetic peptide standard material. No animal systems were used for their manufacture.
Applications:
ELISA
Application Details:
ELISA. For the quantification of Oligomeric Amyloid-beta in CSF, Tissue Homogenates. Please download the detailed product insert for complete instructions for the successful use of this ELISA. Use only as directed.
The ELISA kit box contains 96-well pre-coated strip plate(s), protein standards, QC sample, detection reagents, wash and sample buffers, substrate buffer and detailed protocols.
Product references:
Kasus-Jacobi A et al. (2022) "Selecting Multitarget Peptides for Alzheimers Disease" Biomolecules. 12, 1386 Application: Human, A?142 oligomers. Eid A et al. (2022) "Effects of DDT on Amyloid Precursor Protein Levels and Amyloid Beta Pathology: Mechanistic Links to Alzheimer's Disease Risk" Environ Health Perspect. [Epub ahead of print] Application: Mouse, brain tissue homogenate. Kasus-Jacobi A et al. (2021) "Neutrophil Granule Proteins Inhibit Amyloid Beta Aggregation and Neurotoxicity." Curr Alzheimer Res. 18(5):414-427 Application: Mouse in-vitro assay, cell culture supernatant. Hark TJ et al. (2020) "Pulse-Chase Proteomics of the App Knockin Mouse Models of Alzheimer s Disease Reveals that Synaptic Dysfunction Originates in Presynaptic Terminals." Cell Syst. [Epub ahead of print] Application: Mouse cortical homogenates. Xiao L et al. (2020) "Enzyme-digested Colla Corii Asini (E'jiao) prevents hydrogen peroxide-induced cell death and accelerates amyloid beta clearance in neuronal-like PC12 cells." Neural Regen Res. 15(12): 2270-2 Application: Rat PC12 RIPA cell extract. Hrynchak MV et al. (2020) "Chronic Presence of Oligomeric A? Differentially Modulates Spine Parameters in the Hippocampus and Cortex of Mice With Low APP Transgene Expression." Front Synaptic Neurosci. Apr 24;12:16 Application: Mouse lysate. El-Sayed NA et al. (2019) "Design, synthesis, in vitro and in vivo evaluation of novel pyrrolizine-based compounds with potential activity as cholinesterase inhibitors and anti-Alzheimer's agents." Bioorg Chem. [Epub ahead of print] Application: Human. In-vitro screening of drug candidates. Oh Joo Kweon, Young Chul Youn, Yong Kwan Lim, Mi-Kyung Lee, Hye Ryoun Kim (2019) "Clinical utility of serum hepcidin and iron profile measurements in Alzheimer's disease." J Neurol Sci. [In press] Application: Human serum. Pacheco-Quinto J, Clausen D, Perez-Gonzalez R, Peng H, Meszaros A, Eckman CB, Levy E, Eckman EA (2018) "Intracellular metalloprotease activity controls intraneuronal A? aggregation and limits secretion of A? via exosomes." FASEB J. [Epub ahead of print] Application: Human cell line, mouse brain and organotypic brain slice cultures. Oh SB, Kim MS, Park S, Son H, Kim SY, Kim MS, Jo DG, Tak E, Lee JY (2018) "Clusterin contributes to early stage of Alzheimer's disease pathogenesis." Brain Pathol. [Epub ahead of print] Application: Transgenic mouse brain homogenates. S Liu, S Park, G Allington, F Prelli, Y Sun, M Marta-Ariza, H Scholtzova, G Biswas, B Brown, PB Verghese, PD Mehta, Y-U Kwon and T Wisniewski (2017) "Targeting Apolipoprotein E/Amyloid _ Binding by Peptoid CPO_A?17-21 P Ameliorates Alzheimer's Disease Related Pathology and Cognitive Decline." Sci Rep. 7(1):8009 Application: Transgenic mouse brain homogenates. M Cacciottolo, X Wang, I Driscoll, N Woodward, A Saffari, J Reyes, M L Serre, W Vizuete, C Sioutas, T E Morgan, M Gatz, H C Chui, S A Shumaker, S M Resnick, M A Espeland, C E Finch and J C Chen (2017) "Particulate air pollutants, APOE alleles and their contributions to cognitive impairment in older women and to amyloidogenesis in experimental models." Transl Psychiatry. Jan 31;7(1):e1022. Application: Extracts of E3FAD and E4FAD transgenic mouse brains. Riya Thomas, Paulina Zuchowska, Alan W. J. Morris, Felecia M. Marottoli, Sangeeta Sunny, Ryan Deaton, Peter H. Gann, Leon M. Tai (2016) "Epidermal growth factor prevents APOE4 and amyloid-beta-induced cognitive and cerebrovascular deficits in female mice." Acta Neuropathol Commun. 4(1):111 Application: Tris-extracts of EFAD transgenic mouse brains. Nor Faeizah Ibrahim, Daijiro Yanagisawa, Lina Wati Durani, Hamizah Shahirah Hamezah, Hanafi Ahmad Damanhuri, Wan Zurinah Wan Ngah, Mayumi Tsuji, Yuji Kiuchi, Kenjiro Ono, Ikuo Tooyama (2016) "Tocotrienol-Rich Fraction Modulates Amyloid Pathology and Improves Cognitive Function in A?PP/PS1 Mice." J Alzheimers Dis. [Epub ahead of print]. Application: Tris-extracts of mouse brain homogenates. Jia Luo, Sue H. Lee, Lawren VandeVrede, Zhihui Qin, Manel Ben Aissa, John Larson, Andrew F. Teich, Ottavio Arancio, Yohan D'Souza, Ahmed Elharram, Kevin Koster, Leon M. Tai, Mary Jo LaDu, Brian M. Bennett and Gregory R. J. Thatcher (2016) "A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease." Molecular Neurodegeneration 2016 11:35. Application: Tris-extracts of EFAD transgenic mouse brains. Weiguo Peng, Thiyagarajan M. Achariyar, Baoman Li, Yonghong Liao, Humberto Mestre, Emi Hitomi, Sean Regan, Tristan Kasper, Sisi Peng, Fengfei Ding, Helene Benveniste, Maiken Nedergaard, Rashid Dean (2016) "Suppression of glymphatic fluid transport in a mouse model of Alzheimer's disease." Neurobiology of Disease. Vol. 93, Pages 215-225 Application: TBSX-extracts of mouse cerebral cortex. Mafalda Cacciottolo, Amy Christensen, Alexandra Moser, Jiahui Liu, Christian J. Pike, Conor Smith, Mary Jo LaDu, Patrick M. Sullivan, Todd E. Morgan, Egor Dolzhenko, Andreas Charidimou, Lars-Olof Wahlund, Maria Kristofferson Wiberg, Sara Shams, Gloria Chia-Yi Chiang (2016) "The APOE4 allele shows opposite sex bias in microbleeds and Alzheimer's disease of humans and mice." Neurobiology of Aging. Volume 37, January 2016, Pages 47-57 Application: Tris-extracts of E3FAD and E4FAD transgenic mouse brains. Combes M, Poindron P, Callizot N.(2015) "Glutamate protects neuromuscular junctions from deleterious effects of ?-amyloid peptide and conversely: An in vitro study in a nerve-muscle coculture." J Neurosci. Res. 93(4):633-43 Application: Native Rat neurites & human muscle cell co-culture supernatants. Seo, Dong Han, et al. (2015) "Plasma-enabled sustainable elemental lifecycles: honeycomb-derived graphenes for next-generation biosensors and supercapacitors." Green Chem. 17:2164-2171. Application: Synthetic constructs. Tai, LM (2014) "Amyloid-_ Pathology and APOE Genotype Modulate Retinoid X Receptor Agonist Activity in vivo." J Biol Chem. 289(44):30538-55 Application: EFAD-Tg mice. Liu Y, Liu X, Hao W, Decker Y, Schomburg R, Fulop L, Pasparakis M, Menger MD, Fassbender K. (2014) "IKKbeta Deficiency in Myeloid Cells Ameliorates Alzheimer's Disease-Related Symptoms and Pathology." (2014) J Neurosci. Sep 24;34(39):12982-99 Application: Transgenic Mouse brain lysates, supernatants.
Specificity:
Human. MOAB-2 (mouse IgG2b) is a pan-specific, high-titer antibody to A? residues 1-4 and is highly specific just to amyloid beta peptide. The Biosensis o-A? Elisa detects A? oligomers as validated and described by Youmans KL et al (2012) and Rat by Combes M et al (2015). Rat.
The oligomeric form of Amyloid Beta peptide (A?, 1-42) has been closely linked to Alzheimer's Disease. Several ELISAs targeting A? have been developed; however, these ELISAs are known to cross-react with Amyloid Beta precursor protein (APP) and are poorly characterized against monomeric and oligomeric forms of the peptide. The Biosensis MOAB-2 antibody, developed by LaDu and co-workers (Youmans K. et al. , 2012) , has been shown to specifically detect A?, but not the precursor molecule APP. When utilized in ELISAs, the oligomeric form of A? peptide (o-A?) can be assayed independently of the other forms of the molecule when assayed with the MOAB-2 monoclonal antibody. The Biosensis oligomeric A? ELISA kit is a sandwich ELISA that allows the preferential quantification of oligomeric A? peptides. This kit is exclusive to Biosensis and consists of a pre-coated mouse monoclonal anti-A? capture antibody (MOAB-2), a biotinylated MOAB-2 detection antibody and horseradish peroxidase (HRP)-conjugated streptavidin. The addition of a substrate (3,3',5,5'-tetramethylbenzidine, TMB) yields a colored reaction product which is directly proportional to the concentration of o-A? present in samples and protein standards. The purpose of this kit is the in vitro qualitative measurement of oligomeric A? peptide levels in brain extracts and CSF samples from both transgenic mice and humans relative to a known o-A? standard. The inclusion of a highly validated oligomeric standard results in a unique, ready-to-use ELISA kit. This kit has been configured for research use only and is not to be used in diagnostic or clinical procedures.
Product Type:
ELISA Assay
Species Reactivity:
Human,Rat
Immunogen:
The standard in this ELISA is synthetically manufactured beta-amyloid peptide, amino acids 1-42 of human, HFIP treated and dried.The stabilized oligomeric beta amyloid 1-42 control complex is also constructed from the same synthetic peptide standard material. No animal systems were used for their manufacture.
Applications:
ELISA
Application Details:
ELISA. For the quantification of Oligomeric Amyloid-beta in CSF, Tissue Homogenates. Please download the detailed product insert for complete instructions for the successful use of this ELISA. Use only as directed.
The ELISA kit box contains 96-well pre-coated strip plate(s), protein standards, QC sample, detection reagents, wash and sample buffers, substrate buffer and detailed protocols.
Product references:
Kasus-Jacobi A et al. (2022) "Selecting Multitarget Peptides for Alzheimers Disease" Biomolecules. 12, 1386 Application: Human, A?142 oligomers. Eid A et al. (2022) "Effects of DDT on Amyloid Precursor Protein Levels and Amyloid Beta Pathology: Mechanistic Links to Alzheimer's Disease Risk" Environ Health Perspect. [Epub ahead of print] Application: Mouse, brain tissue homogenate. Kasus-Jacobi A et al. (2021) "Neutrophil Granule Proteins Inhibit Amyloid Beta Aggregation and Neurotoxicity." Curr Alzheimer Res. 18(5):414-427 Application: Mouse in-vitro assay, cell culture supernatant. Hark TJ et al. (2020) "Pulse-Chase Proteomics of the App Knockin Mouse Models of Alzheimer s Disease Reveals that Synaptic Dysfunction Originates in Presynaptic Terminals." Cell Syst. [Epub ahead of print] Application: Mouse cortical homogenates. Xiao L et al. (2020) "Enzyme-digested Colla Corii Asini (E'jiao) prevents hydrogen peroxide-induced cell death and accelerates amyloid beta clearance in neuronal-like PC12 cells." Neural Regen Res. 15(12): 2270-2 Application: Rat PC12 RIPA cell extract. Hrynchak MV et al. (2020) "Chronic Presence of Oligomeric A? Differentially Modulates Spine Parameters in the Hippocampus and Cortex of Mice With Low APP Transgene Expression." Front Synaptic Neurosci. Apr 24;12:16 Application: Mouse lysate. El-Sayed NA et al. (2019) "Design, synthesis, in vitro and in vivo evaluation of novel pyrrolizine-based compounds with potential activity as cholinesterase inhibitors and anti-Alzheimer's agents." Bioorg Chem. [Epub ahead of print] Application: Human. In-vitro screening of drug candidates. Oh Joo Kweon, Young Chul Youn, Yong Kwan Lim, Mi-Kyung Lee, Hye Ryoun Kim (2019) "Clinical utility of serum hepcidin and iron profile measurements in Alzheimer's disease." J Neurol Sci. [In press] Application: Human serum. Pacheco-Quinto J, Clausen D, Perez-Gonzalez R, Peng H, Meszaros A, Eckman CB, Levy E, Eckman EA (2018) "Intracellular metalloprotease activity controls intraneuronal A? aggregation and limits secretion of A? via exosomes." FASEB J. [Epub ahead of print] Application: Human cell line, mouse brain and organotypic brain slice cultures. Oh SB, Kim MS, Park S, Son H, Kim SY, Kim MS, Jo DG, Tak E, Lee JY (2018) "Clusterin contributes to early stage of Alzheimer's disease pathogenesis." Brain Pathol. [Epub ahead of print] Application: Transgenic mouse brain homogenates. S Liu, S Park, G Allington, F Prelli, Y Sun, M Marta-Ariza, H Scholtzova, G Biswas, B Brown, PB Verghese, PD Mehta, Y-U Kwon and T Wisniewski (2017) "Targeting Apolipoprotein E/Amyloid _ Binding by Peptoid CPO_A?17-21 P Ameliorates Alzheimer's Disease Related Pathology and Cognitive Decline." Sci Rep. 7(1):8009 Application: Transgenic mouse brain homogenates. M Cacciottolo, X Wang, I Driscoll, N Woodward, A Saffari, J Reyes, M L Serre, W Vizuete, C Sioutas, T E Morgan, M Gatz, H C Chui, S A Shumaker, S M Resnick, M A Espeland, C E Finch and J C Chen (2017) "Particulate air pollutants, APOE alleles and their contributions to cognitive impairment in older women and to amyloidogenesis in experimental models." Transl Psychiatry. Jan 31;7(1):e1022. Application: Extracts of E3FAD and E4FAD transgenic mouse brains. Riya Thomas, Paulina Zuchowska, Alan W. J. Morris, Felecia M. Marottoli, Sangeeta Sunny, Ryan Deaton, Peter H. Gann, Leon M. Tai (2016) "Epidermal growth factor prevents APOE4 and amyloid-beta-induced cognitive and cerebrovascular deficits in female mice." Acta Neuropathol Commun. 4(1):111 Application: Tris-extracts of EFAD transgenic mouse brains. Nor Faeizah Ibrahim, Daijiro Yanagisawa, Lina Wati Durani, Hamizah Shahirah Hamezah, Hanafi Ahmad Damanhuri, Wan Zurinah Wan Ngah, Mayumi Tsuji, Yuji Kiuchi, Kenjiro Ono, Ikuo Tooyama (2016) "Tocotrienol-Rich Fraction Modulates Amyloid Pathology and Improves Cognitive Function in A?PP/PS1 Mice." J Alzheimers Dis. [Epub ahead of print]. Application: Tris-extracts of mouse brain homogenates. Jia Luo, Sue H. Lee, Lawren VandeVrede, Zhihui Qin, Manel Ben Aissa, John Larson, Andrew F. Teich, Ottavio Arancio, Yohan D'Souza, Ahmed Elharram, Kevin Koster, Leon M. Tai, Mary Jo LaDu, Brian M. Bennett and Gregory R. J. Thatcher (2016) "A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease." Molecular Neurodegeneration 2016 11:35. Application: Tris-extracts of EFAD transgenic mouse brains. Weiguo Peng, Thiyagarajan M. Achariyar, Baoman Li, Yonghong Liao, Humberto Mestre, Emi Hitomi, Sean Regan, Tristan Kasper, Sisi Peng, Fengfei Ding, Helene Benveniste, Maiken Nedergaard, Rashid Dean (2016) "Suppression of glymphatic fluid transport in a mouse model of Alzheimer's disease." Neurobiology of Disease. Vol. 93, Pages 215-225 Application: TBSX-extracts of mouse cerebral cortex. Mafalda Cacciottolo, Amy Christensen, Alexandra Moser, Jiahui Liu, Christian J. Pike, Conor Smith, Mary Jo LaDu, Patrick M. Sullivan, Todd E. Morgan, Egor Dolzhenko, Andreas Charidimou, Lars-Olof Wahlund, Maria Kristofferson Wiberg, Sara Shams, Gloria Chia-Yi Chiang (2016) "The APOE4 allele shows opposite sex bias in microbleeds and Alzheimer's disease of humans and mice." Neurobiology of Aging. Volume 37, January 2016, Pages 47-57 Application: Tris-extracts of E3FAD and E4FAD transgenic mouse brains. Combes M, Poindron P, Callizot N.(2015) "Glutamate protects neuromuscular junctions from deleterious effects of ?-amyloid peptide and conversely: An in vitro study in a nerve-muscle coculture." J Neurosci. Res. 93(4):633-43 Application: Native Rat neurites & human muscle cell co-culture supernatants. Seo, Dong Han, et al. (2015) "Plasma-enabled sustainable elemental lifecycles: honeycomb-derived graphenes for next-generation biosensors and supercapacitors." Green Chem. 17:2164-2171. Application: Synthetic constructs. Tai, LM (2014) "Amyloid-_ Pathology and APOE Genotype Modulate Retinoid X Receptor Agonist Activity in vivo." J Biol Chem. 289(44):30538-55 Application: EFAD-Tg mice. Liu Y, Liu X, Hao W, Decker Y, Schomburg R, Fulop L, Pasparakis M, Menger MD, Fassbender K. (2014) "IKKbeta Deficiency in Myeloid Cells Ameliorates Alzheimer's Disease-Related Symptoms and Pathology." (2014) J Neurosci. Sep 24;34(39):12982-99 Application: Transgenic Mouse brain lysates, supernatants.
Specificity:
Human. MOAB-2 (mouse IgG2b) is a pan-specific, high-titer antibody to A? residues 1-4 and is highly specific just to amyloid beta peptide.The Biosensis o-A? Elisa detects A? oligomers as validated and described by Youmans KL et al (2012) and Rat by Combes M et al (2015). Rat.
This gene encodes a member of the low density lipoprotein receptor (LDLR) family. Low density lipoprotein receptors are cell surface proteins that play roles in both signal transduction and receptor-mediated endocytosis of specific ligands for lysosomal degradation. The encoded protein plays a critical role in the migration of neurons during development by mediating Reelin signaling, and also functions as a receptor for the cholesterol transport protein apolipoprotein E. Expression of this gene may be a marker for major depressive disorder. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.
Product Type:
Antibodies Primary
Antibody Type:
monoclonal
Storage Temp:
4°C -20°C for long term storage
Immunogen:
Purified recombinant fragment of human LRP8 (AA: extra 42-182) expressed in E. Coli.
This gene encodes a member of the low density lipoprotein receptor (LDLR) family. Low density lipoprotein receptors are cell surface proteins that play roles in both signal transduction and receptor-mediated endocytosis of specific ligands for lysosomal degradation. The encoded protein plays a critical role in the migration of neurons during development by mediating Reelin signaling, and also functions as a receptor for the cholesterol transport protein apolipoprotein E. Expression of this gene may be a marker for major depressive disorder. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.
Product Type:
Antibodies Primary
Antibody Type:
monoclonal
Storage Temp:
4°C -20°C for long term storage
Immunogen:
Purified recombinant fragment of human LRP8 (AA: extra 42-182) expressed in E. Coli.
Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. Tissue specificity: Occurs in all lipoprotein fractions in plasma. It constitutes 10-20% of very low density lipoproteins (VLDL) and 1-2% of high density lipoproteins (HDL). APOE is produced in most organs. Significant quantities are produced in liver, brain, spleen, lung, adrenal, ovary, kidney and muscle.
Product Type:
Antibodies Primary
Antibody Type:
monoclonal
Storage Temp:
4°C -20°C for long term storage
Host Animal:
mouse
Immunogen:
Purified recombinant fragment of human ApoE expressed in E. Coli.
X
We use cookies to help personalise and improve your web experience.
By using our website you consent to our use of cookies, some of which may have already been set on your device.
View our Cookie Policy to learn more.
